CathWorks Ltd., a Kfar Saba, Israel-based developer of non-invasive FFR measurements for guiding coronary interventions, completed a $15.8M Series B round of financing.
The round was led by Quark Venture and Triventures with participation from Planven Investments, Pontifax, Corundum Open Innovation, and BioStar Ventures as well as a strategic investor.
The company, which received a CE Mark on its lead product earlier this year, intends to use the funds to conduct a global pivotal trial to support 510K FDA approval.
Founded in 2013 by CEO Guy Lavi, CathWorks develops digital healthcare products for the cardiovascular market. Its lead product is a real time, digital platform for the determination of FFR in the catheterization laboratory during procedures in under 5 minutes using standard angiographic images.
The company uses a proprietary series of algorithms to reconstruct the coronary tree in three dimensions from standard angiograms and to provide the clinician with a complete FFR analysis in all visible coronary arteries simultaneously.